RNAi to treat SARS-CoV-2-variant proofing the next generation of therapies

Loading...
Thumbnail Image
File version
Version of Record (VoR)
Author(s)
McMillan, Nigel AJ
Morris, Kevin
Idris, Adi
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2022
Size
File type(s)
Location
License
http://creativecommons.org/licenses/by/4.0/
Abstract

There is an urgent need to bring new antivirals to SARS-CoV-2 to the market. Indeed, in the last 3 months, we have seen at least two new antivirals approved, molnupiravir and paxlovid. Both are older established antivirals that show some efficacy against SARS-CoV-2. The work by Chang et al (2022) in the current issue of EMBO Molecular Medicine explores the use of short interfering RNAs to directly target SARS-CoV-2 and shows that RNAi is an effective approach to reducing, or even eliminating viral replication, depending on the experimental setting. This antiviral effect results in significant prevention of infection-related pathology in animals. The key feature of this approach, besides its simplicity as naked siRNAs, is that all current variants are covered by this treatment.

Journal Title
EMBO Molecular Medicine
Conference Title
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
© The Author(s) 2022. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Molecular medicine
Biochemistry and cell biology
Science & Technology
Life Sciences & Biomedicine
Medicine, Research & Experimental
Research & Experimental Medicine
INHIBITION
Persistent link to this record
Citation
McMillan, NAJ; Morris, K; Idris, A, RNAi to treat SARS-CoV-2-variant proofing the next generation of therapies, EMBO Molecular Medicine, 2022, 14 (4)
Collections